false
0001176309
0001176309
2026-11-05
2026-11-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
November 5, 2026
ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
| delaware |
|
001-35813 |
|
98-0376008 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1185 Avenue of the Americas, Third Floor,
New York, New York |
|
10036 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
844-967-2633
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
| Title of each class |
|
Trading symbol |
|
Name of each exchange on which registered |
| Common Stock, par value $0.012 |
|
ORMP |
|
The Nasdaq Capital Market,
Tel Aviv Stock Exchange |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On February 20, 2026, a purported stockholder
of Oramed Pharmaceuticals Inc. (the “Company”) filed a putative class action in the Court of Chancery of the State of Delaware
captioned Agnes Lotz v. Oramed Pharmaceuticals Inc., C.A. No. 2026-0244-PAF (Del. Ch.) (the “Action”). The Action challenged
provisions of Article III, Section 11 of the Company’s bylaws governing stockholder action by written consent, alleging that they
violated Sections 213(b) and 228(a) of the Delaware General Corporation Law (“DGCL”).
The Company denies that the challenged provisions
of its bylaws violated the DGCL. However, the Company agreed to amend its bylaws to avoid the distraction and cost of needless litigation.
The Action was mooted on June 28, 2026, when the Company amended its bylaws.
On July 2, 2026, the Court entered an order dismissing
the Action while retaining jurisdiction solely to resolve any application by plaintiff’s counsel for attorneys’ fees and expenses.
Without admitting fault or wrongdoing, the Company agreed to pay plaintiff’s counsel $125,000 in attorneys’ fees and expenses
in connection with the mooted claims.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| November 19, 2026 |
ORAMED PHARMACEUTICALS INC. |
| |
| |
By: |
/s/ Nadav Kidron |
| |
Name: |
Nadav Kidron |
| |
|
President and CEO |
2